Who is sponsoring NCT01611142?

NCT01611142 is sponsored by Kyowa Kirin Co., Ltd..

What condition does NCT01611142 study?

NCT01611142 studies Peripheral T-Cell Lymphoma.

What drugs are being tested in NCT01611142?

Interventions: KW-0761 (mogamulizumab).

What is the status of NCT01611142?

NCT01611142 is currently COMPLETED.

Last reviewed 2024-06-14 · How we verify

Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

NCT01611142 Phase 2 COMPLETED

The primary objective of this study is to determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractory PTCL. KW-0761 targets CCR4. CCR4 is the receptor for macrophage derived chemokines MDC/CCL22 and TARC/CCL17. Chemokines are considered to play a role both in the recruitment of immune and inflammatory cells for anti-tumor response and in the selective homing of neoplastic B and T cells.

Details

Lead sponsor	Kyowa Kirin Co., Ltd.
Phase	Phase 2
Status	COMPLETED
Enrolment	38
Start date	2012-04
Completion	2015-05

Conditions

Peripheral T-Cell Lymphoma

Interventions

KW-0761 (mogamulizumab)

Primary outcomes

Overall Response Rate — every 8 weeks

Countries

Denmark, France, Italy, Netherlands, Spain, United Kingdom